Treat DVT with Low Molecular Weight Heparin

Nurse Practitioner

Volumn 28, Issue 10, 2003, Pages 22-29

  Nadeau, Cheryl ^a   Varrone, Jerry ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85026162677     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/00006205-200310000-00010     Document Type: Article

References (30)

1. Ecklund M: Optimizing the flow of care for prevention and treatment of deep vein thrombosis and pulmonary embolus. AACN Clinical Issues 1995; 6 (4): 588-601.
2. Carroll P: Treating deep venous thrombosis at home with low-molecular-weight heparin. Home Healthcare Nurse January 2000; (suppl.): 3-13.
3. Hirsh J, Hoak J: Management of deep vein thrombosis and pulmonary embolism. Circulation 1996; 93 (12): 2212-2235.
4. Schraibman IG, Milne AA, Royle EM: Home versus in-patient treatment for deep vein thrombosis (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software.
5. Hull RD, Raskob GE, Rosenbloom D, et al: Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs. intravenous heparin. Arch Intern Med 1997; 157: 289-293.
6. Ansell JE, Hickey AD, Kleinschmidt KC, et al: Advancing the treatment of deep venous thrombosis and pulmonary embolism. [serial online]. 2000: 1-32. Available at:. Accessed April 1, 2002.
7. Gould MK, Dembitzer AD, Doyle RL, et al: Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. Ann Intern Med 1999; 130: 800-809.
8. Dolovich LR, Ginsberg JS, Douketis JD, et al: A meta-analysis comparing low-molecular weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med 2000; 160: 181-188.
9. Hull RD, Pineo GF: Economic aspects of deep vein thrombosis therapy and outpatient management. Home Healthcare Consultant 2000; 7 (7): 22-29.
10. Koopman MM, Prandoni P, Piovella F, et al: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334 (11): 682-687.
11. Wells PS, Kovacs MJ, Bormanis J, et al: Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin. Arch Intern Med 1998; 158: 1809-1812.
12. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326 (15): 975-981.
13. The Columbus Investigators: Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337 (10): 657-661.
14. Hyers TM, Agnelli G, Hull RD, et al Antithrombotic therapy for venous thromboembolic disease. CHEST 2001; 119 (suppl. 1): 176S-194S.
15. Hirsh J, Warkentin TE, Shaughnessy SG, et al: Heparin and low-molecular-weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy and safety. CHEST 2001, 119 (suppl. 1): 64S-94S.
16. Hirsh J, Levine MN: Low molecular weight heparin. Blood 1992; 79 (1): 1-12.
17. Dunn AS, Coller B: Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. Am J Med 1999; 106: 660-667.
18. Tapson VF, Hull RD: Management of venous thromboembolic disease. Clin Chest Med 1995; 16 (2): 281-294.
19. Schwarz T, Schmidt B, Beyer J, et al: Eligibility for home treatment of deep vein thrombosis: a prospective study in 202 consecutive patients. J Vasc Surg 2001; 34 (6): 1065-1070.
20. Weitz JI: Low-molecular-weight heparins. N Engl J Med 1997; 337 (10): 688-698.
21. Campbell Betten K: The use of low molecular weight heparin in the initial management of patients with deep vein thrombosis. J Am Acad Nurse Pract 2000; 12 (7): 267-272.
22. Levine M, Gent M, Hirsh J, et al: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996; 334 (11): 677-681.
23. Fareed J, Hoppensteadt DA, Walenga JM: Current perspectives on low molecular weight heparins. Seminars in Thrombosis and Hemostasis 1993; 19 (suppl. 1): 1-11.
24. Lindmarker P, Holmstrom M: Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. J Intern Med 1996; 240 (6): 395-401.
25. Handeland GF, Abildgaard U, Holm HA, et al: Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990; 39 (2): 107-112.
26. Bratt G, Aberg W, Johansson M, et al. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis 1990; 64: 506-510.
27. Holm HA, Ly B, Handeland GF, et al: Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low-molecular-weight heparin. Haemostasis 1986; 16 (suppl. 2): 30-37.
28. O’Brien B, Levine M, Willan A, et al: Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 1999, 159: 2298-3304.
29. Boling PA: American Academy of Home Care Physicians guidelines for deep vein thrombosis treatment. Home Health Care Consultant 2000; March (suppl.): 1-8.
30. McMahan Nagle B. Low molecular weight heparin. RN 1998, April: 40-42.